Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China State FDA Grants Clinical Trial Approval For Celsion's Phase III Liver Cancer Trials

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA granted clinical trial approval to Columbia, Md.-based Celsion to conduct Phase III trials in China as part of the company's global trial program for leading product ThermoDo.

You may also be interested in...



Celsion Signs Licensing Agreement With Japanese Yakult Honsha For Liver Cancer Agent ThermoDox

PERTH, Australia - Columbia, Md.-based biotech firm Celsion signed a licensing agreement with Japan's Yakult Honsha covering Celsion's liposomal platform drug, ThermoDox, a heat-sensitive formulation of doxorubicin to treat liver cancer

Celsion Could File ThermoDox Doxorubicin Delivery System For Liver Cancer By 2010

Company’s proprietary heat-sensitive liposome could provide drug delivery for several cancer types, CEO Tardugno tells “The Pink Sheet” DAILY.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel